Kaskela Law LLC is investigating Gyre Therapeutics, Inc. on behalf of its long-term shareholders to determine if the company or its officers and directors violated securities laws or breached fiduciary duties related to recent corporate actions. The investigation aims to protect shareholder interests and explore legal options for affected investors. Shareholders interested in learning more or participating can contact the law firm for further information and assistance.
Immunocore announced updated Phase 1/2 data for brenetafusp in heavily pretreated advanced melanoma patients, showing a 6-month overall survival rate of 87% and a disease control rate of 52%. The 160 mcg dose demonstrated better clinical outcomes and...
Apple's stock surged 15% in May, driven by optimism around its future in AI, particularly the potential of 'agentic smartphones.' Bank of America raised Apple's price target to $380, highlighting this AI opportunity as a key growth driver. Meanwhile,...
Victoria Hanrahan, a senior executive at Nokia, acquired a total of 44,682 Nokia shares on May 26 and May 28, 2026. The shares were purchased on the New York Stock Exchange at average prices of $16.02 and $15.60 respectively, with a combined average ...
Victoria Hanrahan, a senior manager at Nokia Corporation, purchased a total of 44,682 shares on May 26 and May 28, 2026. The shares were acquired on the New York Stock Exchange at an average price of $15.81 per share. This transaction signals confide...
Silicom Ltd. is rated a buy, trading at a low 2.36x next twelve months (NTM) revenue compared to a 9.51x peer median, despite showing five quarters of sequential growth. The company's design-win model, heavy R&D investment, and expanding edge/securit...
